诺氏疟原虫人血期实验感染模型的建立
本研究制备了经人血清适应的诺氏疟原虫YH1株虫库,并在4名成人中开展剂量递增的静脉接种实验感染研究。2人出现可检测虫血症,最高剂量组2人中仅1人感染;不良事件多为轻度且与接种物无关。
要点
- 最高接种剂量约28万虫体时2人中仅1人建立感染,提示个体易感性差异。
- 1名受试者接种后第17天检出虫体,峰浓度202虫/mL,PMR32为2.33。
- 不良事件多为轻度,与接种物无关。
核心结论
- 制备的诺氏疟原虫YH1-HS虫库可在人体建立显性感染,该模型有潜力用于评估影响个体感染易感性的因素。
研究设计与样本
- 单中心实验感染研究,4名成人静脉接种人血清适应的诺氏疟原虫YH1株感染红细胞,采用约2800虫体起10倍递增的剂量递增策略。
主要发现
- 该受试者32小时疟原虫增殖率为2.33(95%CI 1.66-3.25)。
临床怎么用
- 该模型可用于研究诺氏疟原虫生物学、宿主免疫应答及抗疟药活性,但需注意个体间感染易感性差异。
局限性
- 样本量仅4人,最高剂量组仅2人,感染建立的可重复性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The zoonotic parasite Plasmodium knowlesi is an increasing cause of human malaria in Southeast Asia. We aimed to develop a P. knowlesi induced blood-stage malaria (IBSM) model to facilitate study of parasite biology, host responses to infection, and activity of antimalarial treatments. METHODS: We manufactured and characterized a P. knowlesi parasite bank using the P. knowlesi YH1 strain adapted to grow in human serum, and evaluated this bank in an IBSM study involving four adults intravenously inoculated with P. knowlesi-infected erythrocytes using a dose escalation strategy (10-fold increases from ~2800 parasites). Parasitaemia was monitored by qPCR. All participants received curative treatment with artemether-lumefantrine. Endpoints included safety and infectivity of the P. knowlesi bank. RESULTS: Two of the four participants developed detectable parasitaemia. Participant two (administered ∼28 000 parasites) had detectable parasites (approximately 6 parasites/mL) immediately prior to protocol-defined treatment on day 21. Participant three (administered ∼280 000 parasites) developed detectable parasites on day 17, peaking at 202 parasites/mL just after protocol-defined treatment on day 24; the parasite multiplication rate over 32 hours (PMR32) was 2.33 (95% CI 1.66-3.25). Participant four (also administered ∼280 000 parasites) did not become infected. Adverse events were mostly mild and unrelated to the challenge agent. CONCLUSIONS: A GMP-grade P. knowlesi YH1-HS parasite bank was successfully manufactured and shown to establish patent infection in humans. The finding that only one of two participants became infected at the highest inoculum dose highlights the potential for this IBSM model to evaluate factors influencing inter-individual variability in susceptibility to infection.
引用
- Gower JSE, Webster R, Westaway JAF, et al. Development of an Experimental Human Blood-Stage Model for Studying Plasmodium knowlesi. J Infect Dis. 2026. PMID: 42014043. doi:10.1093/infdis/jiag225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。